Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients
| dc.contributor.author | Jimenez Guiu, Xavier | |
| dc.contributor.author | Huici Sánchez, Malka | |
| dc.contributor.author | Romera Villegas, Antonio | |
| dc.contributor.author | Izquierdo Miranda, Alexandre | |
| dc.contributor.author | Sancho Cerro, Ana | |
| dc.contributor.author | Vila Coll, Ramón | |
| dc.date.accessioned | 2021-05-27T09:46:04Z | |
| dc.date.available | 2021-05-27T09:46:04Z | |
| dc.date.issued | 2021-05-01 | |
| dc.date.updated | 2021-05-26T13:50:41Z | |
| dc.description.abstract | Background: Venous thromboembolic events have been one of the main causes of mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia. The aim of our study was to describe the prevalence of deep vein thrombosis (DVT) in noncritically ill patients with COVID-19 pneumonia and correlate such observations with the thromboprophylaxis received. Methods: We performed a prospective cohort study of 67 patients admitted to the hospital for COVID-19 pneumonia. The diagnosis was confirmed using polymerase chain reaction testing of nasopharyngeal specimens. The deep veins were examined using compression duplex ultrasonography with the transducer on B-mode. The patients were separated into two groups for statistical analysis: those receiving low-molecular-weight heparin prophylaxis and those receiving intermediate or complete anticoagulation treatment. Risk analysis and logistic regression were performed. Results: Of the 67 patients, 57 were included in the present study after applying the inclusion and exclusion criteria; 49.1% were women, and the patient mean age was 71.3 years. All 57 patients had undergone compression duplex ultrasonography. Of these 57 patients, 6 were diagnosed with DVT, for an in-hospital rate of DVT in patients with COVID-19 pneumonia of 10.5%. All the patients who had presented with DVT had been receiving low-molecular-weight heparin prophylaxis. The patients receiving prophylactic anticoagulation treatment had a greater risk of DVT (16.21%; 95% confidence interval, 0.04-0.28; P = .056) compared with those receiving intermediate or complete anticoagulation treatment. We also found a protective factor for DVT in the intermediate or complete anticoagulation treatment group (odds ratio, 0.19; 95% confidence interval, 0.08-0.46; P < .05). Conclusions: Noncritically ill, hospitalized patients with COVID-19 pneumonia have a high risk of DVT despite receipt of correct, standard thromboprophylaxis. | |
| dc.format.extent | 6 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.pmid | 32911110 | |
| dc.identifier.uri | https://hdl.handle.net/2445/177709 | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier Inc. | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.jvsv.2020.08.028 | |
| dc.relation.ispartof | Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, vol. 9, num. 3, p. 592-596 | |
| dc.relation.uri | https://doi.org/10.1016/j.jvsv.2020.08.028 | |
| dc.rights | (c) Society for Vascular Surgery, 2021 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | |
| dc.subject.classification | COVID-19 | |
| dc.subject.classification | Tromboflebitis | |
| dc.subject.other | COVID-19 | |
| dc.subject.other | Thrombophlebitis | |
| dc.title | Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1
Carregant...
- Nom:
- Deep vein thrombosis in noncritically ill patients with coronavirus.pdf
- Mida:
- 179.19 KB
- Format:
- Adobe Portable Document Format